M&A Deal Summary

Veracyte Acquires Decipher Biosciences

On February 3, 2021, Veracyte acquired life science company Decipher Biosciences for 600M USD

Acquisition Highlights
  • This is Veracyte’s 1st transaction in the Life Science sector.
  • This is Veracyte’s largest (disclosed) transaction.
  • This is Veracyte’s 2nd transaction in the United States.
  • This is Veracyte’s 1st transaction in California.

M&A Deal Summary
Date 2021-02-03
Target Decipher Biosciences
Sector Life Science
Buyer(s) Veracyte
Deal Type Add-on Acquisition
Deal Value 600M USD
Advisor(s) Evercore Group (Financial)
Cooley (Legal)

Target

Decipher Biosciences

San Diego, California, United States
Decipher Biosciences, Inc. is a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers. Decipher Biosciences is based in San Diego, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Veracyte

South San Francisco, California, United States
Category Company
Founded 2006
Sector Life Science
Employees815
Revenue 361M USD (2023)
DESCRIPTION

Veracyte is a molecular cytology company. Veracyte seeks to use molecular cytology to improve diagnosis with the promise to help physicians and patients make more informed treatment decisions. Veracyte solution will utilize molecular biomarkers on cytology samples to characterize nodules as benign or suspicious of malignancy. Veracyte was founded in 2006 and is based in South San Francisco, California.

DEAL STATS #
Overall 2 of 4
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 2 of 4
State (California) 1 of 1
Country (United States) 2 of 3
Year (2021) 1 of 2
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-04 Allegro Diagnostics

Maynard, Massachusetts, United States

Allegro Diagnostics Corp. focused on developing genomic tests to improve the preoperative diagnosis of lung cancer.

Buy $21M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-01 HalioDx

Marseille, France

HalioDx is an immuno-oncology diagnostics company providing oncologists and drug development organizations with first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine. HalioDx was founded in 2015 and is based in Marseille, France.

Buy €260M
Mergr

Product

Company

Legal